Germline Mutations Associated with Triple Negative Breast Cancer in US Hispanic and Guatemalan Women using Hospital and Community-Based Recruitment Strategies

Purpose: Identify optimum strategies to recruit Latin American and Hispanic women into genetic studies of breast cancer. We evaluated hospital and community-based recruitment strategies. Methods: We used targeted gene sequencing to identify mutations in DNA from unselected Hispanic breast cancer cases from community and hospital-based recruitment in the US and Guatemala. Results: We recruited 287 Hispanic US women, 38 (13%) from community-based and 249 (87%) from hospital-based strategies. In addition, we ascertained 801 Guatemalan women using hospital-based recruitment. In our experience, a hospital-based approach was more efficient than community-based recruitment. In this study, we sequenced 103 US and 137 Guatemalan women and found 11 and 10 pathogenic variants, respectively. The most frequently mutated genes were BRCA1, BRCA2, CHEK2, and ATM. In addition, an analysis of 287 US Hispanic patients with pathology reports showed a significantly higher percentage of triple-negative disease in patients with pathogenic mutations (41% vs. 15%). Finally, an analysis of mammography usage in 801 Guatemalan patients found reduced screening in women with a lower socioeconomic status (P<0.001). Conclusions: Guatemalan and US Hispanic women have rates of hereditary breast cancer mutations similar to other populations and are more likely to have early age at diagnosis, a family history, and a more aggressive disease. Patient recruitment was higher using hospital-based versus community enrollment. This data supports genetic testing in breast cancer patients to reduce breast cancer mortality in Hispanic women.

[1]  M. Sadchikova,et al.  Triple-negative breast cancer: current treatment strategies and factors of negative prognosis , 2022, Journal of medicine and life.

[2]  Jane E. Carpenter,et al.  Common variants in breast cancer risk loci predispose to distinct tumor subtypes , 2022, Breast Cancer Research.

[3]  Jack A. Taylor,et al.  Common variants in breast cancer risk loci predispose to distinct tumor subtypes , 2022, Breast cancer research : BCR.

[4]  Jaana M. Hartikainen,et al.  Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. , 2021, The New England journal of medicine.

[5]  D. Miglioretti,et al.  Age at initiation of screening mammography by family history of breast cancer in the breast cancer surveillance consortium , 2020, Cancer causes & control : CCC.

[6]  Q. Lu,et al.  Community Outreach and Engagement Strategies to Address Breast Cancer Disparities , 2020, Current Breast Cancer Reports.

[7]  Melissa B. Davis,et al.  Cancer health disparities in racial/ethnic minorities in the United States , 2020, British Journal of Cancer.

[8]  K. Shao,et al.  Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer , 2020, Breast Cancer Research and Treatment.

[9]  C. Castañeda,et al.  Latin American Study of Hereditary Breast and Ovarian Cancer LACAM: A Genomic Epidemiology Approach , 2019, Front. Oncol..

[10]  A. Whittemore,et al.  Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry , 2019, Cancer Causes & Control.

[11]  C. Pérez,et al.  A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico , 2018, Cancers.

[12]  C. Nejjari,et al.  Menstrual and reproductive factors and risk of breast cancer: A case-control study in the Fez region, Morocco , 2018, PloS one.

[13]  R. Schmutzler,et al.  Germline Mutations in Triple-Negative Breast Cancer , 2017, Breast Care.

[14]  Christopher R. Gignoux,et al.  Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25 , 2014, Nature Communications.

[15]  S. Bull,et al.  Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information , 2014, Modern Pathology.

[16]  V. Gawryszewski,et al.  Cervical and female breast cancers in the Americas: current situation and opportunities for action. , 2013, Bulletin of the World Health Organization.

[17]  S. Chanock,et al.  The new sequencer on the block: comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing , 2013, Human Genetics.

[18]  E. John,et al.  Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[20]  Francisco M. De La Vega,et al.  Genomics for the world , 2011, Nature.

[21]  B. Ward,et al.  BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer , 2009, Cancer.

[22]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[23]  Frederick M. Howard,et al.  Epidemiology of Triple-Negative Breast Cancer: A Review. , 2021, Cancer journal.

[24]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.